United States Veterinary Pain Management Market Overview
The United States veterinary pain management market is projected to advance at a 5.10% CAGR during 2026–2035. With 2025 represented by an index value of 100, the market reaches an index value of 164.4 by 2035, indicating a 64.4% cumulative increase over the ten-year period. The indexed presentation preserves the growth trajectory published on the existing report page without inserting an unsupported dollar value where the source currently withholds the amount.
Veterinary pain care is shifting from episodic treatment after surgery or injury toward longer-duration management of osteoarthritis, cancer, dental disease and other chronic conditions. This change is commercially important because chronic therapy creates recurring clinic visits, monitoring requirements and repeat dispensing. The treatment pathway is also becoming more varied: conventional non-steroidal anti-inflammatory drugs remain central, while monoclonal antibodies, local anesthetics, rehabilitation, therapeutic lasers and multimodal protocols broaden the addressable market.
Companion animals generate most demand. AVMA data show continued expansion of the U.S. pet population, while clinical need is reinforced by longer pet lifespans, obesity, orthopedic disease and closer observation of behavioral pain indicators. The constraint is not case availability but continuity of care. Household spending pressure, repeat-treatment costs, difficulty recognizing pain and concern about adverse events can interrupt therapy even after a veterinarian has diagnosed a chronic condition.
Product safety now has a stronger influence on prescribing and post-launch surveillance. In 2025, the U.S. Food and Drug Administration communicated with veterinarians about adverse-event reports associated with Librela, a canine osteoarthritis pain therapy. Such monitoring does not remove the clinical role of newer therapies, but it raises the importance of patient selection, informed discussion, follow-up and pharmacovigilance. Companies with strong clinical education and safety-data capabilities therefore hold an advantage beyond product availability alone.
Key Highlights
- The market is projected to expand at a 5.10% CAGR from 2026 to 2035, raising the market index from 100.0 in 2025 to 164.4 in 2035.
- Therapeutic products account for 74% of 2025 market revenue, while devices and non-drug modalities represent the remaining 26%.
- Companion-animal care contributes 82% of market revenue, reflecting the scale of canine and feline osteoarthritis, postoperative and cancer-pain management.
- NSAIDs retain the leading treatment position with 47% of drug revenue, supported by broad clinical familiarity and multiple oral and injectable options.
- Joint and osteoarthritis pain represents 39% of application revenue, ahead of postoperative pain at 27%.
- Veterinary hospitals and clinics control 69% of distribution revenue because prescription initiation, injection administration and clinical monitoring remain practice-centered.
- The South holds 35% of U.S. revenue, followed by the West at 25%, the Midwest at 22% and the Northeast at 18%.
Treatment Landscape: Chronic Pain Is Replacing the Single-Visit Model
Pain is rarely managed through one intervention when an animal has osteoarthritis, cancer or complex surgery. Veterinarians increasingly combine systemic medication with local anesthetics, weight management, physical rehabilitation, controlled exercise or energy-based devices. This multimodal approach aims to improve comfort without relying on continuous escalation of one drug class.
The commercial effect is a wider treatment ecosystem. An osteoarthritis case may involve an injectable biologic, an oral anti-inflammatory drug, rehabilitation sessions and monitoring. Postoperative protocols can combine perioperative analgesia with a shorter take-home course. Cancer care can require changes in treatment as disease, appetite, mobility and tolerance evolve. Market competition therefore occurs across protocols, not simply between individual products.
Market Dynamics
Osteoarthritis Diagnosis and Longer Pet Lifespans
Canine and feline osteoarthritis creates sustained demand because it is chronic, progressive and closely connected to mobility and quality of life. Greater awareness of subtle signs—reduced jumping, reluctance to use stairs, altered gait, stiffness and behavioral withdrawal—is bringing more cases into clinical discussion. Longer animal lifespans expand the population living with degenerative joint disease and other chronic pain conditions.
New Mechanisms Are Expanding the Treated Population
Monoclonal antibodies have introduced a treatment option distinct from conventional NSAIDs. Solensia became the first FDA-approved treatment for control of osteoarthritis pain in cats, while Librela introduced an injectable anti-NGF option for dogs. These therapies address species and patient groups in which long-term oral administration, adherence or tolerance can be difficult. They also move more treatment activity into veterinary practices because administration and follow-up are clinic-led.
Practice Economics Support Diagnostic and Treatment Bundling
Pain management can be integrated with senior-pet examinations, orthopedic workups, dental procedures, surgery, rehabilitation and chronic-disease monitoring. This bundling improves recognition of pain and creates structured follow-up. Digital mobility questionnaires, gait assessment, owner-recorded videos and quality-of-life scoring can make treatment response easier to document.
Adverse Events and Affordability Limit Persistence
Veterinary analgesics can be associated with gastrointestinal, renal, hepatic, neurologic or injection-related concerns depending on the product and patient. Monitoring requirements increase treatment burden, particularly for older animals with comorbidities. FDA communications concerning post-approval experience reinforce the need for risk-based selection and clear follow-up.
Affordability is another restraint. Chronic therapies create cumulative expenditure rather than a single transaction. Diagnostics, repeat visits, laboratory monitoring, rehabilitation and medication may compete within one household budget. Treatment discontinuation can therefore occur even when clinical response is favorable.
Disruption Analysis: Monoclonal Antibodies Change the Care Pathway
The major disruption is the movement from daily oral administration toward longer-acting clinic-administered biologics for osteoarthritis pain. This changes adherence, inventory, appointment frequency and pharmacovigilance. A monthly injection reduces the difficulty of administering tablets to some animals, but it also requires practices to manage repeat scheduling and monitor response between doses.
The shift does not eliminate conventional analgesics. NSAIDs continue to offer broad familiarity, multiple formulations and utility across acute and chronic cases. Instead, biologics create another branch in a multimodal pathway. The resulting market is less likely to be controlled by a single product class and more likely to reward portfolios that address different species, pain types and treatment settings.
Therapeutic devices create a second disruption. Laser systems, pulsed electromagnetic-field devices and rehabilitation technologies support non-drug treatment, especially where medication tolerance or long-term exposure is a concern. Their adoption depends on clinical evidence, staff training, treatment scheduling and equipment utilization rather than prescription volume.
United States Veterinary Pain Management Market Segmentation Analysis
Product Analysis
Therapeutic products generated 74% of U.S. veterinary pain management revenue in 2025, establishing medication as the leading product category. Prescription medicines are used across postoperative pain, osteoarthritis, trauma, dental procedures and cancer-related discomfort. Their position is strengthened by repeat use in chronic conditions and the entry of species-specific biologics. Devices and non-drug modalities held the remaining 26%. This category includes therapeutic lasers, rehabilitation equipment, pulsed electromagnetic-field systems and related interventions. Device revenue is smaller, but utilization can extend across orthopedic, postsurgical and soft-tissue cases, giving veterinary practices a way to offer repeat treatment without relying exclusively on medication.
Drug-Class Analysis
NSAIDs accounted for 47% of drug-segment revenue in 2025, making them the leading pharmacological class. Their established role reflects clinical familiarity, multiple brands and formulations, and use in both acute and chronic pain. Monoclonal antibodies and other targeted therapies represented 21% and gained value through canine and feline osteoarthritis treatment. Opioids held 16%, concentrated in surgical, traumatic and severe acute-pain settings where controlled administration and regulatory requirements shape usage. Local anesthetics contributed 9%, particularly in perioperative blocks and procedure-specific analgesia. The remaining 7% came from adjunctive products used within multimodal protocols.
Route-of-Administration Analysis
Oral therapies represented 43% of 2025 revenue, supported by NSAIDs and other take-home medicines used in chronic and postsurgical care. Parenteral products followed with 38%. This share is sustained by perioperative injections, hospital-based analgesia and monthly monoclonal-antibody administration. Topical and transdermal products accounted for 12%, serving selected acute, localized and postoperative indications. Other routes, including local and procedure-specific delivery, held 7%. Parenteral revenue is positioned to increase faster than the broader market as clinic-administered biologics gain adoption, while oral products will retain a strong role through accessibility and established prescribing patterns.
Animal-Type Analysis
Companion animals accounted for 82% of total market revenue in 2025. Dogs represented the largest component, contributing 61% of the overall market, as canine osteoarthritis, orthopedic surgery, dental procedures, injury and cancer create demand across medications and devices. Cats contributed 17%, with the species’ share strengthened by greater recognition of feline osteoarthritis and the availability of an FDA-approved targeted therapy. Other companion animals accounted for 4%.
Farm animals generated the remaining 18% of market revenue. Cattle represented the principal livestock component because dehorning, castration, lameness, mastitis, injury and surgical care create pain-management requirements. Equine applications also contribute through musculoskeletal injury, postoperative care and chronic lameness. Adoption in production animals remains influenced by veterinary protocols, withdrawal requirements, welfare standards and the economics of treatment at herd scale.
Application Analysis
Joint pain and osteoarthritis formed the largest application, producing 39% of 2025 revenue. The segment combines long treatment duration with recurring monitoring and spans NSAIDs, monoclonal antibodies, rehabilitation and therapeutic devices. Postoperative pain accounted for 27%, supported by soft-tissue surgery, orthopedic procedures, dentistry and spay-neuter activity. Cancer pain represented 13%, where therapy frequently changes with disease progression and is incorporated into palliative or multimodal care. Trauma and injury contributed 11%, while dental pain and other conditions represented the remaining 10%.
Osteoarthritis is likely to gain further value because improved recognition expands the diagnosed population and longer-acting products increase treatment options. Postoperative care will remain a core application, but protocol standardization and local analgesia may redistribute spending among drug classes rather than producing uniform growth across all products.
Distribution-Channel Analysis
Veterinary hospitals and clinics generated 69% of market revenue in 2025. Their leading share reflects prescription initiation, injectable administration, surgery, diagnostic assessment and monitoring. Retail and veterinary pharmacies accounted for 17%, mainly through eligible oral prescriptions and repeat dispensing. Online pharmacies held 10%, supported by refill convenience and home delivery for recurring companion-animal therapies. Other channels represented 4%, including specialist and institutional routes.
Digital dispensing will expand, but clinic-centered products limit complete channel migration. Injectable biologics, controlled medicines, therapeutic devices and treatments requiring examination remain anchored to veterinary practices. Online channels will compete most strongly in repeat oral medication, where authorization, price visibility and delivery convenience influence refill behavior.
United States Regional Analysis
Southern United States
The South held 35% of U.S. veterinary pain management revenue in 2025, making it the largest regional market. Texas and Florida are the principal contributors, supported by large populations, extensive companion-animal ownership, urban veterinary networks and major livestock activity. Texas alone accounted for 9% of national revenue, combining metropolitan companion-animal demand with cattle and equine care. Florida contributed 6%, with demand concentrated in companion animals, senior-pet care and specialty practices. North Carolina, Georgia, Virginia and Tennessee add meaningful clinic and livestock demand. The region’s growth is tempered by uneven access to specialty services outside large metropolitan areas.
Western United States
The West generated 25% of national revenue in 2025. California held 12% of the U.S. market, the largest state contribution, reflecting its population scale, specialist veterinary infrastructure, pet-health spending and concentration of animal-health innovation. Washington, Colorado, Arizona and Oregon broaden the regional market through growing metropolitan pet populations and strong acceptance of rehabilitation and non-drug modalities. Higher operating costs and veterinary-service prices can raise regional revenue per treated case, while access gaps remain in rural and remote areas.
Midwestern United States
The Midwest accounted for 22% of market revenue in 2025. The region has a balanced demand base across companion animals, cattle, swine, equine care and veterinary teaching institutions. Illinois contributed 4% of national revenue, while Ohio and Michigan each maintained meaningful companion-animal markets. Iowa, Wisconsin, Minnesota, Nebraska and Kansas increase the livestock component. The Midwest is strategically important for therapies that must operate across companion and production-animal protocols, although the economics and regulatory considerations differ sharply between those settings.
Northeastern United States
The Northeast represented 18% of U.S. revenue in 2025. New York accounted for 5% of the national market, followed by Pennsylvania at 4%. Massachusetts, New Jersey, Connecticut and Maryland contribute through dense veterinary networks, referral hospitals and high-value companion-animal care. The region has a lower livestock weighting than the South or Midwest and a greater concentration of specialty, oncology, surgical and rehabilitation services. High treatment costs can raise revenue per case but also intensify affordability constraints for chronic therapy.
Competitive Landscape
The market includes pharmaceutical companies, animal-health specialists and therapeutic-device manufacturers. Zoetis, Elanco, Boehringer Ingelheim, Ceva Santé Animale and Vetoquinol compete through established veterinary channels, clinical education and portfolios spanning acute and chronic care. Assisi Animal Health and laser-therapy companies participate in non-pharmacological treatment.
Competition is increasingly shaped by evidence, safety monitoring, dosing convenience, species-specific labeling and practice workflow. Products that require recurring clinic administration can strengthen veterinary engagement but must demonstrate durable clinical value across repeat visits. Oral medicines compete through familiarity, formulation options and cost. Device suppliers depend on capital justification, practitioner training and the number of cases that can use the equipment.
Company Profiles
Zoetis
Zoetis holds a differentiated osteoarthritis position through Librela for dogs and Solensia for cats. Both products use monoclonal-antibody technology and clinic-administered dosing. The portfolio changes the treatment conversation beyond daily oral medicines, while FDA safety communication concerning Librela increases the importance of post-market evidence, case selection and veterinarian education. Zoetis’ U.S. commercial infrastructure and relationships with companion-animal practices support reach across primary and specialty care.
Elanco Animal Health
Elanco participates through Galliprant and a broader companion-animal portfolio. Galliprant targets canine osteoarthritis pain and inflammation through a prostaglandin-receptor pathway distinct from conventional nonselective approaches. Elanco’s competitive position rests on clinic access, chronic-care engagement and the ability to connect pain management with other companion-animal health categories.
Boehringer Ingelheim Animal Health
Boehringer Ingelheim’s Metacam franchise provides meloxicam-based options across veterinary applications. Its position is supported by long-standing clinical familiarity and a broad animal-health presence. The company competes in an established NSAID category where labeling, dosing, safety monitoring and veterinarian experience strongly influence use.
Ceva Santé Animale
Ceva combines companion- and farm-animal health capabilities and has promoted pain recognition in livestock alongside therapeutic products. This dual-market position is relevant because the clinical, economic and welfare requirements of farm-animal pain differ from companion-animal care. Education around recognizing and treating pain can expand appropriate use where underdiagnosis remains a barrier.
Recent Developments
- September 2025: The FDA approved revised safety labeling for Elanco’s Zenrelia after reviewing supplemental animal-safety information. Although Zenrelia treats dermatologic disease rather than pain, the decision illustrates the level of post-approval evidence and label management affecting veterinary prescribing.
- 2025: FDA made adverse-event records available for Librela covering reports received from May 2023 through June 2025, increasing clinical attention to monitoring and benefit-risk discussion in canine osteoarthritis care.
- 2024: Zoetis continued the U.S. commercialization of Librela following FDA approval, extending the osteoarthritis treatment pathway beyond daily oral therapies.
- 2023: FDA approved Librela as the first monoclonal-antibody treatment administered monthly to control canine osteoarthritis pain in the United States.
- 2022: FDA approved Solensia as the first treatment to control osteoarthritis pain in cats, addressing a species in which pain recognition and long-term oral dosing can be difficult.
- 2022: FDA approved Zorbium, a transdermal buprenorphine product indicated for control of postoperative pain associated with surgical procedures in cats.
Treatment Selection and Procurement Priorities
Clinical evidence must match species, indication and treatment duration. Acute surgical analgesia, chronic osteoarthritis and cancer pain require different endpoints and monitoring. Safety profiles should be assessed against age, renal or hepatic status, concurrent medication and the feasibility of follow-up.
Dosing frequency influences adherence and workflow. Daily oral administration may be practical in one household and difficult in another, while monthly injections require repeat appointments. Clinics evaluating devices should assess case volume, session time, training, maintenance and evidence for each proposed indication.
Distribution and inventory also matter. Injectable biologics create cold-chain, appointment and stock-planning requirements. Controlled substances carry added handling obligations. Reliable supply, clear labeling, technical support and adverse-event reporting processes protect continuity of care.
Market Opportunities
The strongest opportunity lies in longitudinal osteoarthritis management that links diagnosis, treatment, mobility assessment and scheduled follow-up. Feline pain remains under-recognized and offers room for better screening and owner education. Rehabilitation and non-drug modalities can be integrated into orthopedic and senior-pet programs. Livestock protocols offer a separate opportunity where evidence, welfare expectations and practical administration align.
Digital tools can improve continuity by collecting owner-reported mobility and behavior between appointments. Their value depends on integration with clinical decisions rather than stand-alone engagement. Products and services that demonstrate treatment response, flag deterioration and support timely reassessment can reduce discontinuation and improve the quality of chronic-care management.
Strategic Takeaways
- Chronic osteoarthritis care is changing revenue from a short prescription cycle into a monitored treatment pathway involving repeat administration, response assessment and therapy adjustment.
- NSAIDs remain the volume foundation, but monoclonal antibodies and multimodal protocols are redistributing value toward therapies with differentiated mechanisms and clinic-administered dosing.
- Companion-animal demand is dominant, yet livestock pain management remains commercially relevant where welfare programs, surgical procedures and production-health protocols support consistent treatment.
- Safety communication is now part of competitive positioning. Product labeling, adverse-event monitoring, veterinarian education and follow-up guidance can influence persistence as strongly as initial clinical uptake.
- Hospitals and clinics retain control of treatment initiation, but online pharmacies are gaining refill activity for eligible oral medicines and recurring companion-animal prescriptions.
- Regional demand follows pet ownership, veterinary-practice density, household income, livestock concentration and access to specialty care rather than population alone.
- Device companies face a different commercialization cycle from pharmaceutical manufacturers: demonstrations, training, capital budgeting and utilization across multiple conditions determine adoption.
